This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Spent $5.4M Lobbying Government In 3Q

WASHINGTON (AP) ¿ Pfizer Inc., the world's biggest drugmaker, spent $5.4 million lobbying the government in the third quarter on topics including the health care overhaul, government spending on medication, and patent and trade issues, according to a quarterly disclosure report.

The maker of cholesterol fighter Lipitor, impotence pill Viagra and nerve pain treatment Lyrica spent 75 percent more on lobbying than its $3.1 million outlay in the year-ago period.

New York-based Pfizer lobbied on legislation on numerous issues involving the federal health care overhaul. Those included health insurance, prices paid for drugs bought through government programs such as Medicare and Medicaid, information technology, allowing generic versions of expensive biologic drugs, and requiring research comparing the effectiveness of medications and other types of treatment.

Much of its lobbying focused on bills that could lead to greater use of medicines the company makes, including the reauthorization of the State Children's Health Insurance Program, and on veterans' health care issues.

The maker of smoking-cessation drug Chantix also lobbied on coverage for programs to help people quit smoking.

Pfizer, which makes antibiotics such as Zithromax, lobbied on two bills related to the growing problem of germs becoming resistant to antibiotics. The maker of cancer drug Sutent also lobbied on a House bill concerning parity for coverage of cancer drugs,
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $32.79 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%
GOOG $750.26 0.00%
TSLA $231.61 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs